<code id='17C656FC7C'></code><style id='17C656FC7C'></style>
    • <acronym id='17C656FC7C'></acronym>
      <center id='17C656FC7C'><center id='17C656FC7C'><tfoot id='17C656FC7C'></tfoot></center><abbr id='17C656FC7C'><dir id='17C656FC7C'><tfoot id='17C656FC7C'></tfoot><noframes id='17C656FC7C'>

    • <optgroup id='17C656FC7C'><strike id='17C656FC7C'><sup id='17C656FC7C'></sup></strike><code id='17C656FC7C'></code></optgroup>
        1. <b id='17C656FC7C'><label id='17C656FC7C'><select id='17C656FC7C'><dt id='17C656FC7C'><span id='17C656FC7C'></span></dt></select></label></b><u id='17C656FC7C'></u>
          <i id='17C656FC7C'><strike id='17C656FC7C'><tt id='17C656FC7C'><pre id='17C656FC7C'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:entertainment    Page View:51424

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In